The rapid expansion of GLP-1 medicines has changed the weight-management sector, creating new demand for regulated services that can provide treatment alongside continuing clinical support.
Glasgow-based Curely operates within this market as a UK-registered online clinic and pharmacy, with medical weight management now forming the central part of its growth strategy.
Founded around late 2023, the company has placed particular emphasis on GLP-1 treatments such as Mounjaro, which contains tirzepatide, and Wegovy, which contains semaglutide. Curely also provides oral weight-loss treatments and maintains pharmaceutical categories covering women’s health, men’s health, sexual health, skincare, general health and travel.
The business reported monthly revenue of approximately £1 million at its November 2025 peak, with trailing 12-month revenue of roughly £5 million. Its average order value was around £140. For its GLP-1 subscription model, the company estimates customer lifetime value at about six times the monthly subscription cost, or approximately £1,200 per customer.
These figures reflect Curely’s decision to concentrate on clinical weight management rather than treat every pharmaceutical category as an equal commercial priority.
Weight Management Sits at the Center of the Service
Curely’s current strategy is built heavily around weight-loss medicines, particularly GLP-1 treatments. The company serves the UK market and primarily targets women who are seeking medically supported approaches to weight management.
Mounjaro is one of the company’s central treatment options. Manufactured by Eli Lilly, the medicine contains tirzepatide and is administered as a weekly injection. It is generally supplied in pen form, with one pen providing around one month of treatment.
Curely’s service also covers practical questions that arise during treatment, including where to administer injections, how quickly patients may notice changes, possible side effects, and dietary considerations.
The medical importance of GLP-1 drugs has grown significantly in recent years. In a 2026 peer-reviewed review, obesity researcher Dr Alexander M. Chao wrote: “Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care.”
Chao also noted that semaglutide and tirzepatide, originally associated with the treatment of type 2 diabetes, have become leading pharmacological options within obesity treatment.
Curely does not limit its weight-management range to injections. The clinic also offers oral treatment options. Its orlos weight loss pill contains orlistat, providing a different type of medical approach for eligible patients who may not be using an injectable GLP-1 treatment.
Flexible Subscriptions Support Ongoing Treatment
Weight-management medication can involve continuing treatment rather than a single prescription. Curely has structured its main service around monthly subscriptions for weight-loss pens, combining medication access with ongoing clinical management. The subscription model includes several practical features:
- No long-term tie-ins
- No cancellation fees
- The option to pause treatment
- The ability to change dosages
- Free delivery across the UK
These features give patients more control over how treatment fits their circumstances. A dosage may need to change as treatment progresses, while other patients may need to pause or stop following clinical advice.
Curely also provides private online consultations, allowing patients to complete the relevant medical assessment without attending a physical pharmacy for every stage of the process.
The long-term nature of treatment is an important consideration. A 2026 India Today report featuring medical specialists stated that “GLP-1-based medicines have become an important tool in obesity treatment. They can reduce appetite, improve blood sugar control and help patients achieve meaningful weight loss when prescribed appropriately.”
That emphasis on appropriate prescribing is significant for online providers. The convenience of digital access still depends on suitable clinical assessment, prescription management, and patient guidance.
Price Sensitivity Shapes Curely’s Market Position
Cost is another major factor in private weight-management treatment. Weekly injectable medicines can represent an ongoing expense, making price a significant consideration for patients who remain on treatment for several months.
Curely has adopted an aggressive pricing strategy within this market. The approach reflects the company’s view that UK consumers seeking GLP-1 treatment are highly price-sensitive and may compare providers closely before beginning or continuing treatment.
Its subscription model complements that pricing approach. Patients are not locked into a fixed long-term arrangement and can adjust their treatment as circumstances change.
The company’s reported average monthly subscription is approximately £200. Curely estimates that a typical GLP-1 customer remains with the service long enough to generate a lifetime value of around £1,200.
Rather than positioning weight-management medication solely around severe obesity, Curely also uses the concept of “lifestyle optimization” in its wider market strategy. The company seeks to address adults who may be moderately overweight or looking to regain aspects of their previous physical health and activity levels as they get older.
This positioning reflects a broader change in public discussion around pharmacological weight management. GLP-1 medicines are increasingly considered within mainstream obesity care rather than being viewed only as treatments for the most severe cases.
Clinical Oversight Supports a Digital-First Model
Online prescription services depend heavily on patient confidence and medical legitimacy. Curely operates as a registered and regulated UK online pharmacy and is associated with Registered Pharmacy number 9012481.
Its service combines digital consultations with clinical guidance covering medication use, side effects, dosage, and other treatment considerations. The company also uses medical experts, including its superintendent pharmacist, to provide commentary and patient education.
This focus addresses one of the main challenges facing online healthcare providers: combining convenience with appropriate medical oversight. The company’s current model remains focused exclusively on the UK, with free delivery available nationwide.
Curely’s Position in a Changing Weight-Management Market
Curely’s development reflects wider changes in the way prescription weight-management services are delivered. GLP-1 medicines have created growing demand for treatment models that combine medication, clinical assessment, continuing support and convenient access.
The company has responded by making weight management its main strategic priority while retaining a wider range of pharmacy products.
Its position centres on competitive pricing, flexible monthly subscriptions, online consultations and regulated clinical oversight. Curely has also indicated that it intends to respond quickly as new weight-management medicines become available in the UK.
As the pharmaceutical options for obesity continue to develop, providers will increasingly compete on more than medication availability alone. Pricing, clinical support, flexibility and the quality of the patient experience are likely to remain important parts of the market. Curely’s current strategy places those factors at the centre of its UK weight-management service.
